Hemorrhagic complications in patients treated with anticoagulant doses of a low molecular weight heparin (enoxaparin) in routine hospital practice

Clinical and Applied Thrombosis/Hemostasis

Volumn 12, Issue 2, 2006, Pages 199-204

  Ellis, Martin H ^a,b   Hadari, Ruth ^a   Tchuvrero, Noa ^a   Shapira, Shirley ^a   Kovlenko, Irena ^a   Kozmiakova, Mariana ^a   Zissin, Rivka ^a   Elis, Avishay ^a  

^a TEL AVIV UNIVERSITY   (Israel)

^b MEIR MEDICAL CENTER   (Israel)

Author keywords

Complications; Hemorrhage; Low molecular weight heparin; Routine use

Indexed keywords

ACETYLSALICYLIC ACID; ANTIARRHYTHMIC AGENT; ANTIBIOTIC AGENT; ANTICOAGULANT AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENOXAPARIN; GLUCOCORTICOID; HYPOCHOLESTEROLEMIC AGENT; INSULIN; LOW MOLECULAR WEIGHT HEPARIN; NITRATE; NONSTEROID ANTIINFLAMMATORY AGENT; ORAL ANTIDIABETIC AGENT; PROTON PUMP INHIBITOR; WARFARIN; PROTON PUMP;

ABDOMINAL BLEEDING; ADULT; AGED; ANTICOAGULATION; ARTICLE; BLEEDING; CAUSE OF DEATH; CHRONIC LIVER DISEASE; CLINICAL PRACTICE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; FREQUENCY ANALYSIS; GASTROINTESTINAL HEMORRHAGE; HEMATOMA; HEMATURIA; HUMAN; INJECTION SITE BLEEDING; INTESTINAL BLEEDING; KIDNEY DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; MEDICAL DOCUMENTATION; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RETROPERITONEAL HEMORRHAGE; SKIN BLEEDING; TREATMENT DURATION; UNIVERSITY HOSPITAL; VAGINA BLEEDING; WARD; AGE; CHEMICALLY INDUCED DISORDER; DRUG ANTAGONISM; DRUG SCREENING; HOSPITAL; INCIDENCE; KIDNEY FAILURE; LIVER DISEASE; MIDDLE AGED; MORTALITY;

AGE FACTORS; AGED; AGED, 80 AND OVER; ANTICOAGULANTS; DRUG EVALUATION; ENOXAPARIN; FEMALE; HEMORRHAGE; HEPARIN, LOW-MOLECULAR-WEIGHT; HOSPITALS; HUMANS; INCIDENCE; KIDNEY FAILURE; LIVER DISEASES; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PROTON PUMPS; WARFARIN;

EID: 33747794939     PISSN: 10760296     EISSN: None     Source Type: Journal    
DOI: 10.1177/107602960601200208     Document Type: Article

References (12)

1. Hirsh J, Warkentin TE, Shaughnessy SG, et al. Heparin and low-molecular-weight heparin. Chest 2001;119:64S.
2. Weitz J. Low-molecular-weight heparins. N Engl J Med 1997;337:688.
3. Levine MN, Raskob G, Landefeld S, Kearon C. Hemorrhagic complications of anticoagulant treatment. Chest 2001;119:108S.
4. Gurfinkel E, Manos EJ, Mejail RI, et al. Low molecular weight heparin versus regular heparin or aspirin in the treatment of unstable angina or ischemia. J Am Coll Cardiol 1995;26:313.
5. Fragmin and Fast Revascularization during Instability in Coronary artery disease (FRISC II) investigators. Long term low molecular mass heparin in unstable coronary artery disease: FRISC II prospective randomized multicenter study. Lancet 1999;354:701.
6. The Columbus Investigators. Low molecular weight heparin is an effective and safe treatment for deep vein thrombosis and pulmonary embolism. N Engl J Med 1997;337:657.
7. Gould MK, Dembitzer AD, Doyle RL, et al. Low molecular weight heparins compared with unfractionated heparin for the treatment of acute deep venous thrombosis: A meta-analysis of of randomized controlled trials. Ann Int Med 1999;130:800.
8. Goodman SG, Cohen M, Bigonzi F, et al, for the Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-wave Coronary Events Study Group. Randomized trial of low molecular weight heparin (enoxaparin) versus unfractionated heparin for unstable coronary artery disease: One year results of the ESSENCE study. J Am Coll Cardiol 2000;36:693.
9. The Thrombolysis in Myocardial Infarction (TIMI) IIA Trial Investigators. Dose ranging trial of enoxaparin for unstable angina: Results of TIMI IIA. J Am Coll Cardiol 1997;29:1471.
10. Cohen M, Demers C, Gurfinkel EP, et al. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. N Engl J Med 1997;337:447.
11. Zidane M, Schram M, Planken EW, et al. Frequency of major hemorrhage in patients treated with unfractionated intravenous heparin for deep venous thrombosis or pulmonary embolism. Arch Intern Med 2000;160:2369.
12. Greaves M. Limitations of the laboratory monitoring of heparin therapy. Thromb Hemost 2002;87:163.